Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Karolinska Development AB ( (SE:KDEV) ) just unveiled an announcement.
Karolinska Development AB announced that its portfolio company, OssDsign, has successfully treated 10,000 patients in the US with its nanosynthetic bone graft, OssDsign Catalyst. This milestone highlights the product’s rapid adoption and solidified position in the US orthobiologics market, driven by increasing demand from surgeons and hospitals. The company’s ownership in OssDsign is 3%, and the achievement reflects positively on its strategic investments in innovative medical solutions.
More about Karolinska Development AB
Karolinska Development AB is a Nordic life sciences investment company that focuses on identifying and investing in breakthrough medical innovations in the Nordic region. The company collaborates with entrepreneurs and leadership teams to advance these innovations into commercial products, aiming to improve patients’ lives and provide attractive returns for shareholders. With access to world-class medical innovations from institutions like the Karolinska Institutet, the company supports the growth of companies targeting innovative treatments for serious diseases.
Average Trading Volume: 270,778
Current Market Cap: SEK265.2M
See more data about KDEV stock on TipRanks’ Stock Analysis page.